Quick Answer
Pelthos Therapeutics Inc. reported Diluted EPS of $23.04 per share (loss) for fiscal year 2025.
Pelthos Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$23.04 | -61.5% |
| 2024 | -$14.27 | -146.9% |
| 2023 | -$5.78 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.30 | -80.9% | +1.5% |
| June 30, 2025 | -$5.38 | -75.2% | -1581.2% |
| March 31, 2025 | -$0.32 | +41.8% | +89.1% |
| September 30, 2024 | -$2.93 | — | +4.6% |
| June 30, 2024 | -$3.07 | — | -458.2% |
| March 31, 2024 | -$0.55 | — | — |
- Pelthos Therapeutics Inc. showed a decrease of -61.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Pelthos Therapeutics Inc.’s diluted eps has declined by 298.6% (from $5.78 per share (loss) to $23.04 per share (loss)).
- The most recent figure is from Pelthos Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: